Skip to main content

09-22-2020 | EASD 2020 | Conference coverage | News

News in brief

Screening could give 2 years’ extra type 2 diabetes treatment time

Author: Eleanor McDermid


medwireNews: Screening of people aged 40 to 70 years using glycated hemoglobin (HbA1c) would detect type 2 diabetes approximately 2 years earlier than when it is identified due to symptoms or incidental diagnosis, suggests an analysis of the UK Biobank.

Katie Young (University of Exeter, UK) and colleagues found that 1% of 201,465 people with no diabetes diagnosis prior to Biobank recruitment had HbA1c levels of 48 mmol/mol (6.5%) or higher at their baseline assessment.

These people were significantly older than those with lower HbA1c (median 61.1 vs 58.2 years), more likely to be male (60 vs 45%), and had a higher BMI (median 31.0 vs 26.6 kg/m2).

The median time to these people receiving a diabetes diagnosis was 2.3 years, but in a statement to media covering the virtual 56th EASD Annual Meeting, Young noted that 23% of people with elevated HbA1c at the baseline assessment still did not have a diagnosis 5 years later.

She said: “The identification of these patients for whom primary care records are available in UK Biobank gives us a unique opportunity to study the impact of this delay on the risk of developing complications in the future.

“While preliminary results suggest that delays in receiving a diagnosis for those with undiagnosed diabetes did not significantly impact diabetes-related complications in this group of people, further research is required to ascertain whether screening for diabetes in this age group would reduce diabetes-related complications.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

EASD virtual meeting; 21–25 September 2020


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video